Drug intelligence / Profile preview

ARGX-125

Development stage: Preclinical
Lead developer: argenx
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ARGX-125 is a preclinical-stage bispecific monoclonal antibody being developed by argenx. It was identified through the company's Immunology Innovation Program (IIP) and emerged as part of a strategic expansion of the pipeline, specifically mentioned in connection with a deal involving Tensegrity. As of early 2026, argenx has not disclosed the specific biological targets or the primary therapeutic indications for ARGX-125. The molecule represents a key component of argenx's 'Vision 2030' strategy to advance a diverse portfolio of novel antibody-based medicines for severe autoimmune and rare diseases.

Beyond the preview

Go deeper on ARGX-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARGX-125.

Explore the full profile